Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

2

Portfolio Exits

2

About Bruce Montgomery

Bruce Montgomery Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bruce Montgomery News

Genoa Pharmaceuticals raises $62M for clinical trials and names Bruce Montgomery CEO

May 16, 2017

May 16, 2017 at 9:33 am May 16, 2017 at 9:33 am GeekWire Cloud Tech Summit tix here! Bruce Montgomery. (UW Photo) Genoa Pharmaceuticals — a biopharmaceutical company working on treatments for respiratory diseases — was operating under the radar just last week. But the company sprung into the limelight Monday with a $62 million series A round and the appointment of biotechnology veteran Bruce Montgomery as CEO. The company said the round will fund its lead treatment, called Aerodone, through stage II clinical trials, which takes it half way to completing the rigorous clinical trial process required for approval by the FDA. The company was founded by Dr. Mark Surber  in 2011 to develop his work on Aerodone. He served as CEO until handing the reigns to Montgomery and will now serve as the company’s chief scientific officer. Aerodone is an inhalable form of a drug called pirfenidone, a treatment for idiopathic pulmonary fibrosis (IPF), which is a deadly orphan disease that causes extensive lung scarring. Montgomery told GeekWire he first encountered IPF when he was working at biotech company Gilead Sciences, which looked at a potential treatment for the disease. Here’s a disease that kills more people a year than breast cancer, but nobody knows what it is. That treatment didn’t pan out, “but I got quite interested in it and realized: Here’s a disease that kills more people a year than breast cancer, but nobody knows what it is,” he said. Although there are two treatments on the market for IPF, they both come with serious side effects that limit how much a patient can take, meaning they can’t be taken to their full potential. Genoa is hoping to find a better solution in Aerodone. “Unless you get a lung transplant or die of something else, this disease is essentially a death sentence. So that has me interested,” Montgomery said. And importantly, there’s a good chance Genoa’s treatment will work, he said. Genoa’s headquarters and development efforts are based in Seattle and Surber leads the company’s San Diego office, focused on nonclinical support of Aerodone and the company’s research efforts. The company currently has seven employees between the two offices. Montgomery said the clinical trial of Aerodone will need to take place at multiple sites because the disease is relatively rare, but he hopes to have a site in Seattle. Montgomery has long been a leading figure in Seattle’s biotechnology world. He’s native to the city and earned two degrees from the University of Washington. His career includes entrepreneurial ventures, stints as a leading researcher and executive at some of the Pacific Northwest’s most prominent biotech companies, and scientific achievements that have extended or saved the lives of hundreds of thousands of patients. Montgomery said he fielded several questions about when he was going to finally leave Seattle after he was announced as Genoa’s CEO. His response? “In a body bag!” He said Seattle has a “group of great biotech talent” and that he’s excited to continue building biotech companies in the city. Clare McGrane is a GeekWire reporter who covers life sciences, biotechnology and general assignment technology stories, in addition to producing the GeekWire radio show and podcast. A graduate of the University of Washington, she is passionate about nonfiction storytelling, particularly stories about how science impacts our daily lives. Reach her at clare@geekwire.com and follow her @claremcgrane .

Bruce Montgomery Investments

2 Investments

Bruce Montgomery has made 2 investments. Their latest investment was in Athira Pharma as part of their Series A - II on February 2, 2016.

CBI Logo

Bruce Montgomery Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/11/2016

Series A - II

Athira Pharma

$6.5M

Yes

3

1/20/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/11/2016

1/20/2016

Round

Series A - II

Seed VC

Company

Athira Pharma

Subscribe to see more

Amount

$6.5M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

3

10

Bruce Montgomery Portfolio Exits

2 Portfolio Exits

Bruce Montgomery has 2 portfolio exits. Their latest portfolio exit was Athira Pharma on September 18, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/18/2020

IPO

$99M

Public

1

4/9/2020

Asset Sale

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/18/2020

4/9/2020

Exit

IPO

Asset Sale

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.